Local delivery of argatroban in porcine coronary arteries with the Dispatch(TM) catheter - It's efficiency and safety to the arteries following balloon angioplasty

Japanese Pharmacology and Therapeutics

Volumn 25, Issue 12, 1997, Pages 21-28

  Anabuki, Jun ^a  

^a MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Argatroban; Dispatch(TM) catheter; Local drug delivery; Percutaneous transluminal coronary angioplasty (PTCA)

Indexed keywords

ARGATROBAN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SWINE;

EID: 0031417734     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kent KM et al: Long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA); Report from the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol 53(12): 27C-31C, 1984
2. McNamara CA et al: Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 91: 94-98, 1993
3. Weiss RH, Maduri M: The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. J Biol Chem 268(8): 5724-5727, 1993
4. Stouffer GA et al: Thrombin-induced mitogenesis of vascular SMC is partially mediated by autocrine production of PDGF-AA. Am J Physiol 265(3 pt 1): C806-811, 1993
5. Okamoto S et al: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805; The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101(2): 440-446, 1981
6. 2-[(3-methyl-1, 2, 3, 4-tetrahydro-8-quinolinyl) sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 23(1): 85-90, 1984
7. Kumada T, Abiko Y: Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 24(4): 285-298, 1981
8. Tamao Y et al: Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemost 56(1): 28-34, 1986
9. Kawai H et al: Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 278(2): 780-785, 1996
10. Lunven C et al: Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 75(1): 154-160, 1996
11. Lincoff AM et al: Local drug delivery for the prevention of restenosis: Fact, fancy, and future. Circulation 90(4): 2070-2084, 1994
12. Mitchel JF et al: Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system: In vitro, in vivo, and clinical studies. Circulation 91(3): 785-793, 1995
13. Serruys PW et al: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 333(12): 757-763, 1995
14. McKay RG et al: Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter. Cathet Cardiovasc Diagn 33(2): 181-188, 1994
15. Imanishi T et al: Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury. Jpn Circ J 61(3): 256-262, 1997